Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Unlike chemotherapy with its known toxicity towards normal body systems, Namodenoson provides protective effectsRamat Gan, Israel, March 03, ...